Business
MetaVia to Present Data Highlighting DA-1726, a GLP-1/Glucagon Dual Agonist, in a Late-Breaking Poster Presentation at the EASL Congress 2026
MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that a late-breaking abstract highlighting DA-1726, a novel dual oxyntomodulin (OXM) analog targeting both GLP-1 (GLP1R) and glucagon (GCGR) receptors for the treatment of obesity, has been accepted for a poster presentation at the European Association for the Study of the Liver (EASL) Congress 2026, being held May 27–30, 2026 in Barcelona, Spain.
About this update from Metavia Inc.
[{"type":"text","content":"CAMBRIDGE, Mass., May 11, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that a late-breaking abstract highlighting DA-1726, a novel dual oxyntomodulin (OXM) analog targeting both GLP-1 (GLP1R) and glucagon (GCGR) receptors for the treatment of obesity, has been accepted for a poster presentation at the European Association for the Study of the Liver (EASL) Congress 2026, being held May 27–30, 2026 in Barcelona, Spain.","length":530,"tagName":"p"},{"type":"image","alt":"MetaVia Logo (PRNewsfoto/MetaVia Inc.)","displaySize":"","headline":null,"caption":"MetaVia Logo (PRNewsfoto/MetaVia Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":77,"url":"https://media.zenfs.com/en/prnewswire.com/116597eda2a36d52628a741d23461740"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Hl5i49Ek7TPL9D0Is283dw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTEzNg--/https://media.zenfs.com/en/prnewswire.com/116597eda2a36d52628a741d23461740","width":400,"height":77},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/BXqy_Ki.LBwGSMAbmCLXww--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTEyMw--/https://media.zenfs.com/en/prnewswire.com/116597eda2a36d52628a741d23461740","width":400,"height":77}},"href":"https://mma.prnewswire.com/media/2568660/MetaVia_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""Having a late-breaking abstract on DA-1726 accepted for a poster presentation at the prestigious EASL Congress underscores the strength of this asset," stated Hyung Heon Kim, President and Chief Executive Officer of MetaVia. "DA-1726 continues to demonstrate potential for a differentiated, best-in-class profile and is currently being evaluated in a 16-week Phase 1 Part 3 titration study designed to optimize higher dose levels and tolerability, with data expected in the fourth quarter of this year."","length":524,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Title: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DA-1726, an Oxyntomodulin Analogue, in a Higher-Dose Phase 1 Cohort with Exploratory Noninvasive Liver Assessment ","length":184,"tagName":"p"}]},{"val":[{"type":"text","content":"Presenting Author: Chris Fang, Chief Medical Officer, Me...